 | | Raltegravir (Isentress) |  | | Published
November 13, 2007; Updated
October 19, 2011 | Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-07-01 | | | Selected Reference | | 2. | Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles. Abstract 105bLB. | |
|
|
|
